Phase Ib of repotrectinib plus osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer. Aguilar A, Cobo M, Calles A, Azkarate A, et al. Lung Cancer 2026;217:109461.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Aguilar A, Cobo M, Calles A, Azkarate A, et al. Phase Ib of repotrectinib plus osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer. Lung Cancer 2026;217:109461.
PMID: 42155306